

References

This is the reference list to the ACE Clinical Guideline “Mild and moderate atopic dermatitis (eczema) – a journey from flare to care”.

1. Chu DK, Schneider L, Asiniwasis RN, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. *Ann Allergy Asthma Immunol.* 2024;132(3):274-312.
2. Cheok S, Yee F, Song Ma JY, et al. Prevalence and descriptive epidemiology of atopic dermatitis and its impact on quality of life in Singapore. *Br J Dermatol.* 2018;178(1):276-277.
3. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. *J Am Acad Dermatol.* 2014;70(2):338-351.
4. Rajagopalan M, De A, Godse K, et al. Guidelines on Management of Atopic Dermatitis in India: An Evidence-Based Review and an Expert Consensus. *Indian journal of dermatology.* 2019;64(3):166-181.
5. Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences of atopic dermatitis clinical characteristics. *Journal of the American Academy of Dermatology.* 2019;80(2):390-401.
6. Feldman SR, Strowd LC, Lovell KK. *Management of Atopic Dermatitis: Methods and Challenges* 2nd ed. Springer International Publishing; 2024
7. Saeki H, Ohya Y, Arakawa H, et al. English version of clinical practice guidelines for the management of atopic dermatitis 2024. *J Dermatol.* 2025;52(2):e70-e142.
8. Quality Use of Medicines Alliance. Challenges of diagnosis and management of eczema in patients with skin of colour 2024 [cited 17 Sept 2025]. Available from: <https://medcast.com.au/blog/challenges-of-diagnosis-and-management-of-eczema-in-patients-with-skin-of-colour>
9. Gan C, Brand R, Foster RS, et al. Diagnosis, assessment and management of atopic dermatitis in children with skin of colour. *Aust J Gen Pract.* 2023;52(10):673-679.
10. Adawi W, Cornman H, Kambala A, et al. Diagnosing Atopic Dermatitis in Skin of Color. *Dermatol Clin.* 2023;41(3):417-429.
11. Ufodiana CE, Fabowale-Makinde B, Kleyn CE. Atopic Dermatitis in Individuals of Asian and African Ancestry: A Scoping Systematic Review. *Dermatol Pract Concept.* 2023;13(4).
12. Williams HC, Burney PG, Strachan D, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. *Br J Dermatol.* 1994;131(3):397-405.
13. Williams HC, Burney PG, Pembroke AC, et al. Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. U.K. Diagnostic Criteria for Atopic Dermatitis Working Party. *Br J Dermatol.* 1996;135(1):12-17.
14. Williams HC, Burney PG, Pembroke AC, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. *Br J Dermatol.* 1994;131(3):406-416.
15. Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. *Acta Derm Venereol Suppl (Stockh).* 1980;92:44-47.
16. National Institute for Health and Care Excellence (NICE). Atopic eczema in under 12s: diagnosis and management. 2023.
17. Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. *Journal of the American Academy of Dermatology.* 2023;89(1):e1-e20.
18. Quality Use of Medicines Alliance. Eczema Care Plan 2024 [cited October 2, 2025]. Available from: <https://go.medcast.com.au/Eczema-Patient-Care-Plan>
19. Wollenberg A, Kinberger M, Arents B, et al. European Guideline (EuroGuiDerm) on atopic eczema: Living update. *J Eur Acad Dermatol Venereol.* 2025.
20. Lax SJ, Van Vogt E, Candy B, et al. Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis. *Clinical and Experimental Allergy.* 2024;54(12):960-972.
21. Chu DK, Chu AWL, Rayner DG, et al. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. *J Allergy Clin Immunol.* 2023;152(6):1493-1519.

22. Paller AS, Fölster-Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. *J Am Acad Dermatol.* 2020;83(2):375-381.
23. Devasenapathy N, Chu A, Wong M, et al. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. *Lancet Child Adolesc Health.* 2023;7(1):13-25.
24. Fahrback K, Tarpey J, Washington EB, et al. Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis. *Dermatology and therapy.* 2020;10(4):681-694.
25. A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥2 Years, With Mild-moderate AD; ClinicalTrials.gov [Internet]. NCT03539601, terminated; Pfizer. Available from: <https://clinicaltrials.gov/study/NCT03539601>.
26. Xiao X, Wang S, Yang H, et al. Comparison of efficacy and safety of crisaborole ointment 2% versus pimecrolimus cream 1% in the treatment of mild to moderate atopic dermatitis in children: a multicenter, randomized, controlled clinical trial. *Chinese Journal of Dermatology.* 2025;58(5):425-430.
27. Ryan Wolf J, Chen A, Wieser J, et al. Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis. *Journal of the European Academy of Dermatology and Venereology: JEADV.* 2024;38(7):1364 - 1372.
28. Danby SG, Matcher S, Byers R, Taylor R, Sahib S, Andrew P, et al. Novel biophysical skin biomarkers discriminate topical anti-inflammatory treatments based on their potential for local adverse effects. *JEADV Clinical Practice.* 2025;4(1):103-16.
29. Chakraborty D, De A, Khan A, et al. Comparative evaluation of the efficacy and safety of crisaborole ointment (2%) versus tacrolimus ointment (0.1%) for the topical treatment of atopic dermatitis: an open-labeled single-blinded randomized controlled trial. *International Journal of Dermatology.* 2025;64(2):402-404.
30. Tan S, Phan P, Law JY, et al. Qualitative analysis of topical corticosteroid concerns, topical steroid addiction and withdrawal in dermatological patients. *BMJ Open.* 2022;12(3):e060867.
31. Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies. *J Am Acad Dermatol.* 2023;88(5):1008-1016.
32. Eichenfield LF, Simpson EL, Papp K, et al. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. *Am J Clin Dermatol.* 2024;25(4):669-683.
33. Lio P, McCarthy M. Neuronal Changes in Atopic Dermatitis: Insights into Neuroimmunological Changes in AD and Therapeutic Implications. *Journal of Integrative Dermatology.* 2025;1(1).
34. Matteredne U, Böhmer MM, Weisshaar E, et al. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema. *The Cochrane database of systematic reviews.* 2019;1(1):CD012167.
35. Kouwenhoven TA, van Muijen ME, van de Kerkhof PCM, et al. Effectiveness of systemic treatments on pruritus associated with atopic dermatitis: A systematic review in pediatric patients. *Pediatric Dermatology.* 2024;41(1):34-40.
36. Nankervis H, Thomas KS, Delamere FM, et al. Scoping systematic review of treatments for eczema. *Programme Grants Appl Res* 4. 2016.
37. Lax SJ, Harvey J, Axon E, et al. Strategies for using topical corticosteroids in children and adults with eczema. *Cochrane Database Syst Rev.* 2022;3(3):Cd013356.
38. González-López G, Ceballos-Rodríguez RM, González-López JJ, et al. Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis. *Br J Dermatol.* 2017;177(3):688-695.
39. Calzavara-Pinton P, Belloni Fortina A, Bonamonte D, et al. Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA), and the Italian Society of Pediatric Dermatology (SIDerP). *Ital J Dermatol Venerol.* 2021;156(2):184-197.
40. Vazquez-Ortiz M, Angier E, Blumchen K, et al. Understanding the challenges faced by adolescents and young adults with allergic conditions: A systematic review. *Allergy.* 2020;75(8):1850-1880.
41. Chan TC, Wu NL, Wong LS, et al. Taiwanese Dermatological Association consensus for the management of atopic dermatitis: A 2020 update. *J Formos Med Assoc.* 2021;120(1 Pt 2):429-442.
42. Dhar S, De A, Saha A, et al. Intermittent or Sequential Topical Tacrolimus in Atopic Dermatitis:

- Systematic Review and Meta-Analysis. *Cureus*. 2023;15(12):e50640.
43. Eichenfield LF, Stein Gold LF, Lynde C, et al. Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis. *Dermatology and Therapy*. 2024;14(4):875-892.
 44. Wang S, Ma L, Shu H, et al. Early relief of clinical symptoms and the improvement during the maintenance period of childhood atopic dermatitis: a multicentre clinical study of crisaborole ointment. *Acta Dermato-Venereologica*. 2023;103:14-15.
 45. Yew YW, Alagappan U, Aw D, et al. Updated consensus guidelines for management of moderate-to-severe atopic dermatitis in Singapore: Integrating biologics, Janus kinase inhibitors and conventional therapies. *Ann Acad Med Singap*. 2024;53(11):670-682.
 46. Chu AWL, Wong MM, Rayner DG, et al. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. *J Allergy Clin Immunol*. 2023;152(6):1470-1492.
 47. Yingying C, Min X, Jinglin X, et al. Probiotics for the Treatment of Atopic Dermatitis in Adults: A Systematic Review and Meta-Analysis. *Indian J Dermatol*. 2025;70(4):221.
 48. Wang L, Xu L. The impact of prebiotics, probiotics and synbiotics on the prevention and treatment of atopic dermatitis in children: an umbrella meta-analysis. *Front Pediatr*. 2025;13:1498965.
 49. Wang HZ, Hayles EH, Fiander M, et al. Probiotics in infants for prevention of allergic disease. *Cochrane Database Syst Rev*. 2025;6(6):Cd006475.
 50. Ha YJ, Tak KH, Lee JL, et al. Polynucleotides Enhance Skin Barrier Function and Reduce Inflammation in a 2,4-Dinitrochlorobenzene-Induced Mouse Model of Atopic Dermatitis. *Skin Res Technol*. 2025;31(6):e70189.
 51. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. *Journal of the American Academy of Dermatology*. 2024;90(2):e43-e56.
 52. Santos AF, Riggioni C, Agache I, et al. EAACI guidelines on the management of IgE-mediated food allergy. *Allergy*. 2025;80(1):14-36.
 53. Gonzalez ME. Management of severe, refractory atopic dermatitis (eczema) in children: UpToDate Inc. ; 2025 [cited October 10, 2025]. Available from: <https://www.uptodate.com/contents/management-of-severe-refractory-atopic-dermatitis-eczema-in-children>
 54. Tay YK, Chan YC, Chandran NS, et al. Guidelines for the Management of Atopic Dermatitis in Singapore. *Ann Acad Med Singap*. 2016;45(10):439-450.
 55. Wang V, Boguniewicz J, Boguniewicz M, et al. The infectious complications of atopic dermatitis. *Ann Allergy Asthma Immunol*. 2021;126(1):3-12.
 56. National Institute for Health and Care Excellence (NICE). Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing. National Institute for Health and Clinical Excellence - Clinical Guidelines. 2021.
 57. Totté JEE, van der Feltz WT, Hennekam M, et al. Prevalence and odds of *Staphylococcus aureus* carriage in atopic dermatitis: a systematic review and meta-analysis. *British Journal of Dermatology*. 2016;175(4):687-695.
 58. George SM, Karanovic S, Harrison DA, et al. Interventions to reduce *Staphylococcus aureus* in the management of eczema. *The Cochrane database of systematic reviews*. 2019;2019(10).
 59. Williamson DA, Carter GP, Howden BP. Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns. *Clin Microbiol Rev*. 2017;30(3):827-860.
 60. Nicolae Dopcea G, Dopcea I, Nanu AE, et al. Resistance and cross-resistance in *Staphylococcus* spp. strains following prolonged exposure to different antiseptics. *J Glob Antimicrob Resist*. 2020;21:399-404.
 61. Elizalde-Jiménez IG, Ruiz-Hernández FG, Carmona-Cruz SA, et al. Global Antimicrobial Susceptibility Patterns of *Staphylococcus aureus* in Atopic Dermatitis: A Systematic Review and Meta-Analysis. *JAMA Dermatol*. 2024;160(11):1171-1181.
 62. Tam VH, Kabbara S, Vo G, et al. Comparative pharmacodynamics of gentamicin against *Staphylococcus aureus* and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2006;50(8):2626-2631.
 63. Gonzalez Moreno M, Trampuz A, Di Luca M. Synergistic antibiotic activity against planktonic and biofilm-embedded *Streptococcus agalactiae*, *Streptococcus pyogenes* and *Streptococcus oralis*. *J Antimicrob Chemother*. 2017;72(11):3085-3092.
 64. Dumycz K, Osinka K, Feleszko W. Contact allergens in topical corticosteroid vehicles: analysis of product composition. *Contact Dermatitis*. 2017;76(4):254-255.
 65. Warshaw EM, Shaver RL, DeKoven JG, et al. Patch Test Reactions Associated With Topical

Medications: A Retrospective Analysis of the North American Contact Dermatitis Group Data (2001-2018). *Dermatitis*. 2022;33(2):144-154.

66. Andrade LF, Ju T, Abdi P, et al. Lack of Evidence for the Efficacy of Antifungal Medications to Treat Atopic Dermatitis: A Systematic Review. *JEADV Clinical Practice*. 2024;4:400-406.